Brief: Vincerx Pharma Announces Compelling Clinical Efficacy Of Enitociclib In Combination With Venetoclax And Prednisone In Lymphoma
07/01/2024 20:01
Jan 7 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA ANNOUNCES COMPELLING CLINICAL EFFICACY OF
ENITOCICLIB IN COMBINATION WITH VENETOCLAX AND PREDNISONE IN
LYMPHOMA
* VINCERX PHARMA - REMAINS ON TARGET TO REPORT EARLY
CLINICAL DATA
FROM LEAD VERSAPTX™ PLATFORM COMPOUNDS, VIP236 (EARLY 2024) AND
VIP943 (MID 2024)
Source text for Eikon: ID:nGNX4Y9hFY
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign